19 completed, 17 active not recruiting, 13 terminated, 6 recruiting. 48 Phase 2, 20 Phase 1, 10 Phase 3.
Follow Tiragolumab: new trials by email Literature Review of Tiragolumab trials Research Report on Tiragolumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) Tiragolumab, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT) - Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-08-15 | 2026-02-19 | |
| STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1 Tiragolumab, Ivonescimab - Lung Squamous Cell Carcinoma, Anti-PD1/PDL1 Antibody | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-07-28 | 2025-08-05 | |
| Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma Atezolizumab, Biospecimen Collection, Magnetic Resonance Imaging - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-04-30 | 2024-12-30 | |
| Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) Tiragolumab, Atezolizumab, Radiation Therapy - Advanced Solid Malignancies | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 7 | 2025-04-13 | 2026-10-07 |
| A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary Atezolizumab, Tiragolumab - Cancer | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 4 | 2025-04-11 | 2026-10-06 |
| Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab - Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC) | Phase 2 | Active not recruiting | University of Colorado, Denver | 13 | 2025-03-25 | 2025-10-02 |
| Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures Atezolizumab 1200 mg IV, Tiragolumab 600 mg IV - Metastatic Cancer Lung, Advanced Lung Cancer | Phase 2 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-30 | 2026-03-23 | |
| A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) Atezolizumab, Tiragolumab - Solid Tumors | Phase 2 | Withdrawn | Hoffmann-La Roche | 2024-11-30 | 2024-12-24 | |
| NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial Tiragolumab, Atezolizumab, Ipilimumab - Metastatic Breast Cancer | Phase 2 | Recruiting | The Netherlands Cancer Institute | 60 | 2024-06-12 | 2024-09-19 |
| A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy Atezolizumab, Tiragolumab, Placebo - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Terminated | Hoffmann-La Roche | 56 | 2024-03-21 | 2026-06-10 |
| Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients Tiragolumab, Atezolizumab - Solid Tumor, Adult | Phase 2 | Recruiting | Omico | 96 | 2023-12-15 | 2024-11-15 |
| Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC Atezolizumab, Tiragolumab - NSCLC | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 178 | 2023-12-07 | 2026-10-01 |
| A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma Atezolizumab, Bevacizumab, Tiragolumab - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 62 | 2023-12-05 | 2026-09-15 |
| Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors Tiragolumab and atezolizumab - Head and Neck Neoplasms, MSI-H Cancer | Phase 2 | Recruiting | University Medical Center Groningen | 97 | 2023-10-18 | 2025-03-30 |
| Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial Atezolizumab, Biopsy Procedure, Biospecimen Collection - Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2023-09-26 | 2026-10-14 |
| Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients Tiragolumab - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Unknown | National Taiwan University Hospital | 32 | 2023-09-18 | 2024-02-02 |
| A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) Atezolizumab, Bevacizumab, Tiragolumab - Hepatocellular Carcinoma | Phase 3 | Active not recruiting | Hoffmann-La Roche | 687 | 2023-09-14 | 2025-12-31 |
| Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases Tiragolumab, Atezolizumab, Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Terminated | Liza Villaruz, MD | 3 | 2023-08-10 | 2026-01-22 |
| Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). Tiragolumab, Atezolizumab, Standard of Care - Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 29 | 2023-06-02 | 2026-06-02 |
| A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study Ipatasertib, Tiragolumab, Atezolizumab - Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 100 | 2023-06-01 | 2026-10-02 |
Showing 20 of 63. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Neoplasms (5) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Melanoma (3) · Small Cell Lung Carcinoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Carcinoma, Squamous Cell (2) · Esophageal Neoplasms (2) · Lung Neoplasms (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Triple Negative Breast Neoplasms (2)
Hoffmann-La Roche (32) · M.D. Anderson Cancer Center (6) · Genentech, Inc. (4) · National Cancer Institute (NCI) (4) · Alliance Foundation Trials, LLC. (2) · Alain Algazi (1) · Centre Georges Francois Leclerc (1) · Georgetown University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Liza Villaruz, MD (1) · Mayo Clinic (1) · National Taiwan University Hospital (1) · Omico (1) · SCRI Development Innovations, LLC (1)
United States (44) · South Korea (27) · Spain (23) · Taiwan (19) · Australia (18) · China (17) · France (17) · United Kingdom (16) · Germany (14) · Poland (13) · Italy (12) · Japan (10) · Thailand (10) · Brazil (9) · Canada (9)
Alain Algazi, MD (1) · Byoung Chul Byoung Chul (1) · Chia-Hsien Cheng, Cheng (1) · David Thomas, PHD, FRACP (1) · Derk JA de Groot, MD PhD (1) · Ecaterina Dumbrava, MD (1) · Evanthia Galanis, MD (1) · Florian Eichhorn, Dr. (1) · George Ansstas, M.D. (1) · Hannah Robinson, MD (1) · Helen Ross, MD (1) · Jianjun Zhang, MD (1) · Jibran Ahmed (1)
PMID 36940261, PMID 41449151, PMID 34825282, PMID 35576957, PMID 36931243, PMID 37651261, PMID 37768658, PMID 37946136, PMID 37976444, PMID 38105505, PMID 38365756, PMID 38418879, PMID 38451273, PMID 38858106, PMID 38861301, PMID 39707623, PMID 39855251, PMID 40147985, PMID 40234093, PMID 40896848, PMID 40993242, PMID 41297162, PMID 41392942, PMID 41449142, PMID 41529226, PMID 42060297, PMID 42507965, PMID 42507968, PMID 42628839
2023 (7), 2019 (4), 2016 (3), 2017 (1), 2018 (1), UM1CA186690 (1), UM1CA228823 (1)